Cwm LLC Has $2.14 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cwm LLC decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 2,438 shares of the biopharmaceutical company’s stock after selling 256 shares during the quarter. Cwm LLC’s holdings in Regeneron Pharmaceuticals were worth $2,141,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in REGN. Meyer Handelman Co. grew its position in Regeneron Pharmaceuticals by 11.4% in the third quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock valued at $3,485,000 after acquiring an additional 435 shares during the period. Stifel Financial Corp lifted its holdings in Regeneron Pharmaceuticals by 12.2% during the 3rd quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock valued at $25,537,000 after purchasing an additional 3,385 shares during the last quarter. LPL Financial LLC lifted its holdings in Regeneron Pharmaceuticals by 9.3% during the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after purchasing an additional 3,479 shares during the last quarter. Cavalier Investments LLC boosted its position in Regeneron Pharmaceuticals by 88.6% in the third quarter. Cavalier Investments LLC now owns 4,436 shares of the biopharmaceutical company’s stock valued at $3,651,000 after buying an additional 2,084 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in Regeneron Pharmaceuticals by 32.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after buying an additional 1,221 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of Regeneron Pharmaceuticals stock opened at $890.68 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The firm has a 50-day moving average of $949.30 and a 200-day moving average of $893.27. The stock has a market cap of $97.76 billion, a PE ratio of 25.63, a PEG ratio of 2.60 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same period in the previous year, the company earned $10.96 EPS. The business’s revenue for the quarter was up .6% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Analysts Set New Price Targets

REGN has been the subject of a number of research reports. Bank of America raised their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 20th. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. Barclays raised their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $977.77.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total value of $793,093.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,325,338. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,022 shares of company stock worth $10,552,991. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.